SET welcomes MEDEZE, starting trading on 15 October

MEDEZE Group PCL, the leader in stem cell banking services with world-class standards, is ready to be traded on the Stock Exchange of Thailand on 15 Oct with a market capitalization at the IPO price of 9,612 million baht, using the abbreviation 'MEDEZE' in the securities trading. Mr. Amnuay Chiramahaphoka, Assistant Manager, Issuer Group 1, Stock Exchange of Thailand (SET), revealed that the Stock Exchange of Thailand welcomes Medize Group to list and start trading on the Stock Exchange of Thailand in the Service Industry Group, Medical Business Category, using the abbreviation 'MEDEZE' on October 15, 2024. MEDEZE has been engaged in the business of providing stem cell analysis, separation, cultivation, and storage services for newborns (extracted from blood and umbilical cord tissue) and the general public (extracted from adipose tissue) for over 14 years. The service covers long-term cryopreservation of stem cells in accordance with the international standards of the Association for the Advancement of Bl ood and Biotherapies (AABB) from the United States, and has expanded its services to include testing the potential of immune cells (NK Cells) with a team of doctors and specialists. In addition, the continuous development of services with innovation and modern technology has made MEDEZE trusted by both domestic and international users. MEDEZE has a paid-up capital of 534 million baht, with a par value of 0.50 baht per share. It offered 268 million ordinary shares for the first time to the public (IPO), by offering to persons at the discretion of the underwriter not less than 201 million shares, benefactors of the company not more than 40.20 million shares, and directors, executives, and employees of the company and its subsidiaries not more than 26.80 million shares between October 2-4, 2024 at a price of 9 baht per share, for a total fundraising value of 2,412 million baht and a securities value at the IPO price of 9,612 million baht, with Yuanta Securities (Thailand) Co., Ltd. acting as financial advisor a nd manager of the underwriting and underwriting of the ordinary shares. Dr. Veerapol Khemarangsan, Chief Executive Officer of Mediz Group PCL, revealed that this fundraising and listing on the Stock Exchange of Thailand will help enhance the company's growth. It plans to expand its hair follicle cell bank business and invest in installing a robotic cell culture system. Stem cells are the heart of disease prevention, treatment, body rejuvenation, or even aging. The company focuses on using automated innovations to increase the efficiency and effectiveness of its services in order to maintain its leadership in the modern stem cell industry in Thailand and the ASEAN region. MEDEZE has the top 3 shareholders after the IPO as follows: 1) Khemarangsan family group 58.29% 2) Dr. Chamnan Sakulpaisan 13.84% 3) Assoc. Prof. Dr. Rangsan Palpai 2.77% The IPO offering price is determined by the price-to-earnings ratio (PE ratio) of 35.55 times, calculated from the net profit in the past 4 quarters from July 1, 2023 to J une 30, 2024, divided by the total number of ordinary shares issued and paid-up after this offering (Fully Diluted), resulting in net profit per share of 0.25 baht. The company has a dividend payment policy at a rate of not less than 30 percent of net profit from the separate financial statements after deducting corporate income tax and all types of reserves as required by law. Source: Thai News Agency